Forte Biosciences (FBRX) Income from Continuing Operations (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Income from Continuing Operations came in at 22136000.0 in Q1 2026, down 41.39% year-on-year from 37768223.19 in Q1 2025, and up 10.07% on a QoQ basis from 24614000.0 in Q4 2025.
Forte Biosciences (FBRX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Income from Continuing Operations data on file, last reported at 22136000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 41.39% year-over-year to 22136000.0 in Q1 2026; TTM through Mar 2026 was 107154000.0, a 140.3% decrease from a year earlier, with the FY2025 full-year figure at 73522000.0, down 2655.51% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 22136000.0, up from 24614000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for FBRX reached as high as 2818000.0 in Q1 2022 and fell as low as 35794000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 12166882.35 across 5 years, with a median of 8657000.0 in 2024.
- Across the five-year window, Income from Continuing Operations jumped 90.32% in 2022 and slumped 313.47% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 5004000.0 in 2022, then dropped by 28.12% to 6411000.0 in 2023, then declined by 15.93% to 7432000.0 in 2024, then slumped by 231.19% to 24614000.0 in 2025, then increased by 10.07% to 22136000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 22136000.0 in Q1 2026, 24614000.0 in Q4 2025, and 35794000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Forte Biosciences | 994.79 Mn | 936.59 Mn | - | -22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -24.61 Mn |
| Sep 30, 2025 | -35.79 Mn |
| Jun 30, 2025 | -24.61 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | -7.43 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -12.85 Mn |
| Mar 31, 2024 | -7.83 Mn |
| Dec 31, 2023 | -6.41 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.12 Mn |
| Mar 31, 2023 | -6.93 Mn |
| Dec 31, 2022 | -5.00 Mn |
| Sep 30, 2022 | -3.52 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -2.82 Mn |
| Dec 31, 2021 | -12.89 Mn |
| Sep 30, 2021 | -8.74 Mn |
| Jun 30, 2021 | -28.92 Mn |